Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Ambroxol-theophylline-7-acetate
1. Ambroxol Acefyllinate
2. Ambromucil
3. Broncomnes
4. Surfolase
5. 96989-76-3
6. Ambroxol Theophyllinacetate
7. 179118-73-1
8. Ambroxol-theophylline-7-acetate
9. Ambroxol Theophyllinate
10. 0hm1e174tn
11. 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic Acid
12. Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, Trans-, Mono(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7h-purine-7-acetate) (salt)
13. Unii-0hm1e174tn
14. Schembl1650322
15. Chembl4297663
16. Dtxsid60914235
17. Glxc-26022
18. Bcp28655
19. Ambroxol Acefyllinate [mart.]
20. Akos015899892
21. Ambroxol Acefyllinate [who-dd]
22. Db13141
23. Ambroxol Theophyllinate [who-dd]
24. Ambromucil Pound>>ambroxol-theophylline-7-acetate
25. Q19607226
26. (1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7h-purin-7-yl)acetic Acid--4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexan-1-ol (1/1)
27. 7h-purine-7-acetic Acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-, Compd. With Trans-4-(((2-amino-3,5-dibromophenyl)methyl)amino)cyclohexanol (1:1)
| Molecular Weight | 616.3 g/mol |
|---|---|
| Molecular Formula | C22H28Br2N6O5 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 616.04674 g/mol |
| Monoisotopic Mass | 614.04879 g/mol |
| Topological Polar Surface Area | 154 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 645 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
Acebrophylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Lead Product(s): Acebrophylline,Acetylcysteine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2024
Lead Product(s) : Acebrophylline,Acetylcysteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acebrophylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 30, 2024
Details:
Acebrophylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Bronchitis.
Lead Product(s): Acebrophylline,Acetylcysteine
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Kwang-Ha Yoo
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 14, 2023
Lead Product(s) : Acebrophylline,Acetylcysteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Kwang-Ha Yoo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acebrophylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Bronchitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2023
Details:
Acebrophylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bronchitis.
Lead Product(s): Acebrophylline,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2016
Lead Product(s) : Acebrophylline,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acebrophylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bronchitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 08, 2016
Details:
Surfolase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Acebrophylline,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Enzyme
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 24, 2015
Lead Product(s) : Acebrophylline,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Surfolase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 24, 2015
Details:
Surfolase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Acebrophylline,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Enzyme
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2015
Lead Product(s) : Acebrophylline,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Surfolase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
February 27, 2015
Details:
Surfolase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Acebrophylline,HT-002-01
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Enzyme
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 08, 2012
Lead Product(s) : Acebrophylline,HT-002-01
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Surfolase is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 08, 2012
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Italy
Ambroxol-Theophylline-7-Acetate
Brand Name : Broncomnes
Dosage Form :
Dosage Strength : 30 Bust Grat 100 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Ambroxol-Theophylline-7-Acetate
Brand Name : Broncomnes
Dosage Form :
Dosage Strength : The Scir 200 Ml 10 Mg/Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : Generic
Registration Country : India
Ambroxol-Theophylline-7-Acetate
Brand Name :
Dosage Form : CAPSULE
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsule
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : SR Tablet
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : Italy
Ambroxol-Theophylline-7-Acetate
Brand Name : Ambromucil
Dosage Form :
Dosage Strength : 30 Bust Grat 100 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Ambroxol-Theophylline-7-Acetate
Brand Name : Surfolase
Dosage Form :
Dosage Strength : To 30 Bust Grat 100 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Ambroxol-Theophylline-7-Acetate
Brand Name : Ambromucil
Dosage Form :
Dosage Strength : The Scir 200 Ml 10 Mg/Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Ambroxol-Theophylline-7-Acetate
Brand Name : Surfolase
Dosage Form :
Dosage Strength : The Scir 200 Ml 1%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
ABOUT THIS PAGE
87
PharmaCompass offers a list of Acebrophylline API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Acebrophylline manufacturer or Acebrophylline supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Acebrophylline manufacturer or Acebrophylline supplier.
A Acebrophylline manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Acebrophylline, including repackagers and relabelers. The FDA regulates Acebrophylline manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Acebrophylline API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Acebrophylline manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Acebrophylline supplier is an individual or a company that provides Acebrophylline active pharmaceutical ingredient (API) or Acebrophylline finished formulations upon request. The Acebrophylline suppliers may include Acebrophylline API manufacturers, exporters, distributors and traders.
click here to find a list of Acebrophylline suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Acebrophylline Drug Master File in Korea (Acebrophylline KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Acebrophylline. The MFDS reviews the Acebrophylline KDMF as part of the drug registration process and uses the information provided in the Acebrophylline KDMF to evaluate the safety and efficacy of the drug.
After submitting a Acebrophylline KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Acebrophylline API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Acebrophylline suppliers with KDMF on PharmaCompass.
A Acebrophylline written confirmation (Acebrophylline WC) is an official document issued by a regulatory agency to a Acebrophylline manufacturer, verifying that the manufacturing facility of a Acebrophylline active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Acebrophylline APIs or Acebrophylline finished pharmaceutical products to another nation, regulatory agencies frequently require a Acebrophylline WC (written confirmation) as part of the regulatory process.
click here to find a list of Acebrophylline suppliers with Written Confirmation (WC) on PharmaCompass.
Acebrophylline Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Acebrophylline GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Acebrophylline GMP manufacturer or Acebrophylline GMP API supplier for your needs.
A Acebrophylline CoA (Certificate of Analysis) is a formal document that attests to Acebrophylline's compliance with Acebrophylline specifications and serves as a tool for batch-level quality control.
Acebrophylline CoA mostly includes findings from lab analyses of a specific batch. For each Acebrophylline CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Acebrophylline may be tested according to a variety of international standards, such as European Pharmacopoeia (Acebrophylline EP), Acebrophylline JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Acebrophylline USP).
